UNASSIGNED: @entity3528 is a  @entity74 requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A  total of 333 adult hemodialysis and peritoneal dialysis @entity1 were analyzed. All @entity1 received conventional care prior to initiation of a  @entity4046 -based regimen. During the study, treatment components, e.g. @entity4046 , active @entity560 analogues and @entity4613 binders, were adapted to individual @entity1 requirements and treatment dynamics were documented. Overall, the mean intact parathyroid hormone (iPTH) increased from 64.2   pmol/l to 79.6   pmol/l under conventional therapy and decreased after @entity4046 initiation to 44.0   pmol/l after 12 months (mean decrease between baseline and 12 months -45%). @entity460 remained within the normal range throughout the study and @entity3151 ranged around the upper limit of normal. The @entity8 : Improving Global Outcomes (KDIGO) target achievement for iPTH increased from 44.5% of @entity1 at baseline to 65.7% at 12 months, corrected @entity460 from 58.9% to 51.9% and @entity3151 from 18.4% to 24.4%. On average, approximately 30% of @entity1 adapted their regimen from one observation period to the next. The reasons for changing a  given regimen were to attain or maintain any of the bone mineral markers within recommended targets and to avoid developments to extreme values. Some regional differences in practice patterns were identified. No new safety signals emerged. In conclusion, @entity4046 appears to be a  necessary treatment component to achieve recommended targets. The detailed composition of the treatment mix should be adapted to @entity1 requirements and reassessed on a  regular basis.

Management of secondary hyperparathyroidism: practice patterns and outcomes of @entity4046 treatment with or without active XXXX in Austria and Switzerland - the observational TRANSIT Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['Kidney Disease'] @entity4613 :: ('D010710', 'Chemical') :: ['phosphate'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['Secondary hyperparathyroidism'] @entity74 :: ('MESH:D030342', 'Disease') :: ['complex disorder'] @entity4046 :: ('MESH:C476217', 'Chemical') :: ['cinacalcet'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['Calcium', 'calcium'] @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin  D']
@entity560 :: (MESH:D014807,Chemical) :: ['vitamin  D']
